Metformin on the Presence of COVID-19 Symptoms 6 Months After Infection: The ACTIV-6 Randomized Clinical Trial
Clinical Infectious Diseases · 04.06.2026
DOI: 10.1093/cid/ciag335 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 04.06.2026. Verfasst von Carolyn T Bramante und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Minnesota Medical School, Minneapolis, MN. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
Background
We conducted a quadruple-blinded, randomized, placebo-controlled trial of metformin for treating acute SARS-CoV-2 infection to prevent long COVID symptoms in low-risk adults.
Methods
The ACTIV-6 platform evaluated repurposed medications for mild to moderate COVID-19. Between 19 September 2023 and 1 May 2024, 2983 outpatient adults ≥30 years with confirmed SARS-CoV-2 infection and ≥2 COVID-19 symptoms were included within 7 days of symptom onset from 90 sites. Participants were randomized to metformin or placebo for 14 days. Postacute sequelae of SARS-CoV-2 or death (PASCD) was ascertained by asking whether participants had symptoms they attributed to COVID-19 on day 180. Secondary outcomes included clinician-diagnosed long COVID.
Results
The median age was 47 years (interquartile range 38–57); 63% were female; 47% were Hispanic/Latino; 83% reported ≥1 prior COVID-19 infections or ≥2 SARS-CoV-2 vaccines. There were no deaths. Overall, 96 (3.2%) reported COVID-19 symptoms on day 90, 101 (3.4%) on day 120, and 79 (2.6%) on day 180. The adjusted risk of symptoms on day 180 was 0.8 percentage points lower with metformin (95% credible interval [CrI] −2.2 to 0.6) with a posterior probability of efficacy (PPE) for preventing symptoms of 0.83, risk ratio 0.79 (95% CrI 0.474 to 1.230). Compared with placebo, the risk of clinician-diagnosed long COVID was 0.7 percentage points lower with metformin (95% CrI −1.5 to 0.1); PPE 0.96; risk ratio 0.495 (95% CrI 0.155–0.995).
Conclusions
In low-risk adults, most with prior immunity, metformin did not exceed the efficacy threshold of 0.975 for PASC. Metformin reduced the risk of clinician-diagnosed long COVID. Clinical Trail Registration ClinicalTrials.gov (NCT04885530).
Autor:innen und Institutionen
- Department of Medicine, University of Minnesota Medical School, Minneapolis, MN.
- School of Data Science, University of Virginia, Charlottesville, VA.
- Weill Cornell Medicine, New York, NY.
- Vanderbilt University Medical Center, Nashville, TN.
- Department of Medicine, Duke University School of Medicine, Durham, NC.
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
ORCID-Profile: Ahmad Mourad, Orlando Quintero Cardona, G Michael Felker, Susanna Naggie
Förderung
- NIDDK NIH HHS
- NCATS NIH HHS
- National Center for Advancing Translational Sciences
- Biomedical Advanced Research and Development Authority
- Vanderbilt University Medical Center Clinical and Translational Science
Zitieren
APA
Bramante, C. T., Stewart, T. G., Boulware, D. R., McCarthy, M. W., Gao, Y., Rothman, R. L., Mourad, A., Thicklin, F., Cohen, J. B., Garcia Del Sol, I. T., Shah, N. S., Mehta, M., Quintero Cardona, O., Scott, J., Ginde, A. A., Castro, M., Jayaweera, D., Sulkowski, M., Gentile, N., …, & Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators (2026). Metformin on the Presence of COVID-19 Symptoms 6 Months After Infection: The ACTIV-6 Randomized Clinical Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag335
Vancouver
Bramante CT, Stewart TG, Boulware DR, McCarthy MW, Gao Y, Rothman RL, et al. Metformin on the Presence of COVID-19 Symptoms 6 Months After Infection: The ACTIV-6 Randomized Clinical Trial. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag335
BibTeX
@article{Bramante2026,
author = {Bramante, Carolyn T and Stewart, Thomas G and Boulware, David R and McCarthy, Matthew W and Gao, Yue and Rothman, Russell L and Mourad, Ahmad and Thicklin, Florence and Cohen, Jonathan B and Garcia Del Sol, Idania T and Shah, Nirav S and Mehta, Manisha and Quintero Cardona, Orlando and Scott, Jake and Ginde, Adit A and Castro, Mario and Jayaweera, Dushyantha and Sulkowski, Mark and Gentile, Nina and McTigue, Kathleen and Felker, G Michael and Collins, Sean and Dunsmore, Sarah E and Adam, Stacey J and Lindsell, Christopher J and Hernandez, Adrian F and Naggie, Susanna and Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators, Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators},
title = {Metformin on the Presence of COVID-19 Symptoms 6 Months After Infection: The ACTIV-6 Randomized Clinical Trial},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciag335}
}
EUVIMED